Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch
GeekWire
JULY 7, 2021
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Net losses were $5.3 Icosavax Photo).
Let's personalize your content